These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25252697)

  • 1. Efficacy of desvenlafaxine succinate for menopausal hot flashes.
    Tella SH; Gallagher JC
    Expert Opin Pharmacother; 2014 Nov; 15(16):2407-18. PubMed ID: 25252697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptoms? A meta-analysis and meta-regression of randomized double-blind controlled studies.
    Berhan Y; Berhan A
    Ethiop J Health Sci; 2014 Jul; 24(3):209-18. PubMed ID: 25183927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desvenlafaxine: a therapeutic option for treatment of menopausal hot flashes.
    Archer DF
    Maturitas; 2010 May; 66(1):1-2. PubMed ID: 20211532
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials.
    Sun Z; Hao Y; Zhang M
    Gynecol Obstet Invest; 2013; 75(4):255-62. PubMed ID: 23548358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
    Speroff L; Gass M; Constantine G; Olivier S;
    Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
    Pinkerton JV; Constantine G; Hwang E; Cheng RF;
    Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women.
    Stubbs C; Mattingly L; Crawford SA; Wickersham EA; Brockhaus JL; McCarthy LH
    J Okla State Med Assoc; 2017 May; 110(5):272-274. PubMed ID: 28649145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venlafaxine and desvenlafaxine in the management of menopausal hot flashes.
    Johnson ED; Carroll DG
    Pharm Pract (Granada); 2011 Jul; 9(3):117-21. PubMed ID: 24367464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
    Archer DF; Seidman L; Constantine GD; Pickar JH; Olivier S
    Am J Obstet Gynecol; 2009 Feb; 200(2):172.e1-10. PubMed ID: 19110224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause.
    Archer DF; Pinkerton JV; Guico-Pabia CJ; Hwang E; Cheng RF;
    Menopause; 2013 Jan; 20(1):47-56. PubMed ID: 23266840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
    Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
    Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desvenlafaxine succinate for major depressive disorder.
    Sproule BA; Hazra M; Pollock BG
    Drugs Today (Barc); 2008 Jul; 44(7):475-87. PubMed ID: 18806899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms.
    Cheng RJ; Dupont C; Archer DF; Bao W; Racketa J; Constantine G; Pickar JH
    Climacteric; 2013 Feb; 16(1):17-27. PubMed ID: 22646219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venlafaxine hydrochloride for the treatment of hot flashes.
    Schober CE; Ansani NT
    Ann Pharmacother; 2003 Nov; 37(11):1703-7. PubMed ID: 14565812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
    Pinkerton JV; Archer DF; Guico-Pabia CJ; Hwang E; Cheng RF
    Menopause; 2013 Jan; 20(1):38-46. PubMed ID: 23266839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desvenlafaxine for the treatment of major depressive disorder.
    Kornstein SG; McIntyre RS; Thase ME; Boucher M
    Expert Opin Pharmacother; 2014 Jul; 15(10):1449-63. PubMed ID: 24914479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.
    Pae CU; Park MH; Marks DM; Han C; Patkar AA; Masand PS
    Curr Opin Investig Drugs; 2009 Jan; 10(1):75-90. PubMed ID: 19127490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial.
    Joffe H; Partridge A; Giobbie-Hurder A; Li X; Habin K; Goss P; Winer E; Garber J
    Menopause; 2010; 17(5):908-16. PubMed ID: 20581724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review.
    Handley AP; Williams M
    J Am Assoc Nurse Pract; 2015 Jan; 27(1):54-61. PubMed ID: 24944075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing vasomotor symptoms in women after cancer.
    Pinkerton JV; Santen RJ
    Climacteric; 2019 Dec; 22(6):544-552. PubMed ID: 31081391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.